NuvalentNUVL
NUVL
About: Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
Employees: 127
0
Funds holding %
of 6,780 funds
0
Analysts bullish %
of 9 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
74% more first-time investments, than exits
New positions opened: 47 | Existing positions closed: 27
42% more capital invested
Capital invested by funds: $5.04B [Q2] → $7.15B (+$2.11B) [Q3]
29% more repeat investments, than reductions
Existing positions increased: 71 | Existing positions reduced: 55
22% more funds holding in top 10
Funds holding in top 10: 9 [Q2] → 11 (+2) [Q3]
12% more funds holding
Funds holding: 172 [Q2] → 192 (+20) [Q3]
3.78% less ownership
Funds ownership: 112.34% [Q2] → 108.56% (-3.78%) [Q3]
30% less call options, than puts
Call options by funds: $46.7M | Put options by funds: $66.5M
Research analyst outlook
9 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$99
5%
upside
Avg. target
$116
23%
upside
High target
$135
43%
upside
9 analyst ratings
8 positive
89%
1 neutral
11%
0 negative
0%
BMO Capital Etzer Darout 45% 1-year accuracy 10 / 22 met price target | 42%upside $134 | Outperform Maintained | 13 Nov 2024 |
UBS David Dai 0% 1-year accuracy 0 / 9 met price target | 6%upside $100 | Neutral Initiated | 24 Oct 2024 |
JP Morgan Anupam Rama 47% 1-year accuracy 24 / 51 met price target | 32%upside $125 | Overweight Maintained | 4 Oct 2024 |
Guggenheim Kelsey Goodwin 33% 1-year accuracy 1 / 3 met price target | 11%upside $105 | Buy Maintained | 16 Sept 2024 |
Wedbush David Nierengarten 43% 1-year accuracy 23 / 54 met price target | 21%upside $115 | Outperform Maintained | 16 Sept 2024 |
Financial journalist opinion
Neutral
PRNewsWire
1 week ago
Nuvalent to Participate in the Piper Sandler 36th Annual Healthcare Conference
CAMBRIDGE, Mass , Nov. 26, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D., Chief Executive Officer, and Alexandra Balcom, Chief Financial Officer, will participate in a fireside chat during the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024, at 3:30 p.m.
Neutral
PRNewsWire
3 weeks ago
Nuvalent Highlights Corporate and Pipeline Achievements, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2024 Financial Results
Achievement of all anticipated 2024 milestones and accelerated development timelines reinforce progress on OnTarget 2026 operating plan towards first approved product in 2026 Leading medical oncologist Alice Shaw, M.D., Ph.D. appointed to Scientific Advisory Board Strong cash position of $1.2 billion, including proceeds from upsized $575 million public offering, expected to extend operating runway into 2028 CAMBRIDGE, Mass.
Positive
Seeking Alpha
2 months ago
Nuvalent: Promising Data Keeps Validating Pipeline And Platform
Nuvalent's lead candidates, NVL-520 and NVL-655, show promising efficacy and safety in Phase 1/2 trials. Both drugs have received FDA Breakthrough Therapy and orphan drug designations, with pivotal Phase 2 data expected in 2025 and potential approvals by 2026. The company completed a $500 million secondary offering, reflecting strong investor interest and providing the cash runway through Phase 3.
Neutral
PRNewsWire
2 months ago
Nuvalent Announces Closing of Upsized Public Offering of Common Stock
CAMBRIDGE, Mass. , Sept. 18, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the closing of its previously announced upsized underwritten public offering of 5,750,000 shares of Class A common stock, which includes 750,000 shares of Class A common stock sold pursuant to the exercise in full by the underwriters of their option to purchase additional shares, at a price to the public of $100.00 per share.
Positive
Zacks Investment Research
2 months ago
Nuvalent Stock Moves Up 20% in a Week: What's Driving the Rally?
The upside comes after NUVL reported encouraging data on two experimental lung cancer therapies.
Positive
Seeking Alpha
2 months ago
Nuvalent: NSCLC Program Now Lends Credibility Towards 2025 Pivotal Data Releases
Nuvalent, Inc. achieved positive data from the phase 1/2 ALKOVE-1 study, using NVL-655 for the treatment of patients with ALK-mutant NSCLC. Positive data achieved from phase 1/2 ARROS-1 study, using zidesamtinib for the treatment of patients with ROS-1 mutant NSCLC. The global non-small cell lung cancer market size is projected to reach $36.9 billion by 2031; 3% to 5% are ALK-positive and then 1% to 3% are ROS-1 positive.
Neutral
PRNewsWire
2 months ago
Nuvalent Announces Pricing of Upsized Public Offering of Common Stock
CAMBRIDGE, Mass. , Sept. 16, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the pricing of an upsized underwritten public offering of 5,000,000 shares of Class A common stock at a price to the public of $100.00 per share.
Positive
Benzinga
2 months ago
Nuvalent Stock Jumps On ESMO Data Presentation, Seeks To Raise $350M Via Equity
Over the weekend, Nuvalent, Inc. NUVL highlighted the presentation of updated data from Phase 1 dose-escalation portions of the ongoing ARROS-1 Phase 1/2 trial of zidesamtinib and ALKOVE-1 Phase 1/2 trial of NVL-655, at the European Society for Medical Oncology (ESMO) Congress 2024.
Negative
Investors Business Daily
2 months ago
Nuvalent Flies On 'Multibillion-Dollar' Potential, While Iteos Crashes On Patient Deaths
Biotech stocks Nuvalent and Iteos diverged Monday on updates for their lung cancer treatments at the ESMO meeting in Madrid.
Positive
Barrons
2 months ago
Cancer Biotech Nuvalent's Stock Jumps on Positive Data
Biotech Nuvalent unveiled updates on two experimental cancer medicines over the weekend. Analysts say each could be the best in their category.
Charts implemented using Lightweight Charts™